27th Jun 2013 16:36
Cyprotex PLC ("Cyprotex" or the "Company")
Director dealings
27 June 2013 - The Company received notification that John Dootson, Chief Financial Officer of the Company, acquired 100,000 ordinary shares in the Company on 27 June 2013 at a price of 5.5 pence per share. As a result of this purchase, Mr Dootson has an interest in 689,285 ordinary shares in the Company representing approximately 0.31 per cent. of the Company's total voting rights.
In addition, the Company received notification that Dr. Anthony Baxter, Chief Executive Officer of the Company, acquired 94,059 ordinary shares in the Company on 27 June 2013 at a price of 5.44 pence per share. As a result of this purchase, Dr. Baxter has an interest in 1,161,744 ordinary shares in the Company representing approximately 0.52 per cent. of the Company's total voting rights.
In addition, the Company received notification that Steve Harris, Chairman of the Company, acquired 98,000 ordinary shares in the Company on 27 June 2013 at a price of 5.44 pence per share. As a result of this purchase, Steve Harris has an interest in 1,605,142 ordinary shares in the Company representing approximately 0.72 per cent. of the Company's total voting rights.
For further information:
Cyprotex PLC | Tel: +44 (0) 1625 505 100 |
Dr Anthony Baxter, Chief Executive Officer John Dootson, Chief Financial Officer Mark Warburton, Chief Operating Officer and Legal Counsel | www.cyprotex.com |
N+1 Singer (Nomad and broker to Cyprotex) | Tel: +44 (0)20 7496 3000 |
Shaun Dobson Jenny Wyllie
| [email protected]@n1singer.comwww.nplus1singer.com |
FTI Consulting | Tel: +44 (0) 20 7831 3113 |
Simon Conway Mo Noonan | www.fticonsulting.com
|
Notes to Editors
About Cyprotex PLC
Cyprotex is based in Macclesfield, near Manchester in the UK, and Watertown, MA in the US and is listed on the AIM market of the London Stock Exchange (CRX). The company was established in 1999 and works with more than 700 partners ranging from small biotechs to large pharma companies. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The company's core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services and predictive modelling using PBPK and QSAR techniques, including Cloe® PK for in vivo PK prediction. For more information, see www.cyprotex.com.
Related Shares:
CRX.L